KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $135.9 million.

  • West Pharmaceutical Services' Accumulated Expenses rose 8489.8% to $135.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $135.9 million, marking a year-over-year increase of 8489.8%. This contributed to the annual value of $135.9 million for FY2025, which is 8489.8% up from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Accumulated Expenses is $135.9 million, which was up 8489.8% from $111.8 million recorded in Q3 2025.
  • West Pharmaceutical Services' Accumulated Expenses' 5-year high stood at $135.9 million during Q4 2025, with a 5-year trough of $65.7 million in Q1 2023.
  • In the last 5 years, West Pharmaceutical Services' Accumulated Expenses had a median value of $81.2 million in 2024 and averaged $88.0 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Accumulated Expenses plummeted by 3396.39% in 2022 and then surged by 8489.8% in 2025.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Accumulated Expenses stood at $116.3 million in 2021, then plummeted by 33.96% to $76.8 million in 2022, then soared by 37.89% to $105.9 million in 2023, then plummeted by 30.59% to $73.5 million in 2024, then surged by 84.9% to $135.9 million in 2025.
  • Its last three reported values are $135.9 million in Q4 2025, $111.8 million for Q3 2025, and $93.4 million during Q2 2025.